Businessman use tablet and smart phone for Stock Market istock photo for BL | Photo Credit: Orientfootage

Shares of Max Healthcare Institute rallied over a per cent on Thursday after global brokerage Citi maintained its buy rating at a target price of ₹1,240.

The stock rose as much as 6.58 per cent to ₹1,093.70 on the NSE, compared with its previous close of ₹1,026.15.

Citi maintained its positive stance on the stock, describing the current weakness as a buying opportunity and indicating confidence in the company’s long-term growth prospects.

According to the brokerage, Max Healthcare is “preparing for a long haul” and is expected to deliver improvements in its balance sheet and return on capital employed (RoCE) despite pursuing an aggressive expansion strategy.

Citi said near-term challenges are likely to be transient, adding that the disruption in the oncology business should be largely absorbed in the first half of the fiscal year.

The brokerage also expects the company to post a compound annual growth rate (CAGR) of around 20 per cent in EBITDA between FY26 and FY30.

The bullish commentary triggered buying interest in the stock, making Max Healthcare one of the top gainers on the benchmark indices during the session.

Published on June 18, 2026